Amarin Corp has filed a patent for a method of reducing triglycerides in patients on atorvastatin therapy. The method involves administering a pharmaceutical composition containing eicosapentaenoic acid or a derivative thereof. The composition must contain at least 80% ethyl eicosapentaenoate. GlobalData’s report on Amarin Corp gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Amarin Corp, Cancer treatment biomarkers was a key innovation area identified from patents. Amarin Corp's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Method of reducing triglycerides in a subject on atorvastatin therapy
A recently filed patent (Publication Number: US20230310372A1) describes a method for reducing triglycerides in patients undergoing atorvastatin therapy. The method involves administering a pharmaceutical composition containing ethyl eicosapentaenoate, a type of fatty acid derivative, to the patient.
The patent claims specify the dosage and composition of the pharmaceutical composition. Claim 1 states that the composition should contain at least 80% ethyl eicosapentaenoate by weight. Claim 2 suggests administering 1 to 4 capsules per day, with each capsule containing 1 gram of ethyl eicosapentaenoate.
The patent also includes claims related to the impact of ethyl eicosapentaenoate on the pharmacokinetics of atorvastatin. Claims 3 to 8 state that the maximum concentration (Cmax), area under the curve (AUC0-24), and time to reach maximum concentration (Tmax) of atorvastatin should not be significantly altered when ethyl eicosapentaenoate is administered alongside atorvastatin. The alteration in these parameters should be no more than 35% to 15% compared to a control group that only receives atorvastatin.
Claims 9 to 14 specify the baseline triglyceride levels of the patients and the desired outcomes of the method. The method aims to reduce triglycerides without increasing LDL-C levels, compared to baseline or a control group that only receives atorvastatin.
The patent also includes claims related to the composition of the capsules. Claims 15 to 18 state that the capsules should contain at least 80% ethyl eicosapentaenoate by weight, with increasing percentages specified in each claim. Claims 19 to 22 limit the presence of docosahexaenoic acid and its esters in the composition to no more than 20% to 3% by weight.
Finally, claim 23 describes a method of co-administering atorvastatin and 2 or 4 grams per day of ethyl eicosapentaenoate. This co-administration should result in steady-state plasma concentrations of atorvastatin within a range of 70% to 135% of the mean concentrations observed in patients receiving atorvastatin alone.
In summary, the patent outlines a method for reducing triglycerides in patients on atorvastatin therapy by administering a pharmaceutical composition containing ethyl eicosapentaenoate. The claims specify the dosage, composition, and desired outcomes of the method, as well as the impact on the pharmacokinetics of atorvastatin.
To know more about GlobalData’s detailed insights on Amarin Corp, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
